HORMONAL CONTRACEPTION IN YOUNG WOMEN: PREFERENCES, EXPECTATIONS, ADHERENCE


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To define contraceptive methods preferred by young women, their expectations of chosen hormonal means to prevent an unwanted pregnancy, and a way to enhance their adherence. Subjects and methods. The results of a sociological survey of 1007young women, conducted in 2012, were analyzed. A structured interview, a method to retrieve information from a questionnaire containing open- questions, was applied; 402 Moscow students were anonymously interviewed. Results. The survey demonstrated the current characteristics of marriage, reproductive, and contraceptive behavior in 20-24-year-old women: a decline in the number of registered marriages (29.3%), stabilization of birth rates at a level of 90%o, a 26% reduction in abortion rates in the past 15 years; condom preferences (59%), coitus interruptus (26%), and combined oral contraceptives (COCs) (33%) with a low adherence to the latter. The main expectations of the women in choosing a hormonal contraceptive were its high efficacy, minimum side effects, convenience and easiness to use, and good menstrual cycle control. The above parameters were used to compare a number of COCs. The latter in a 24/4 regimen containing 20 fig of ethinylestradiol and 3 fig of drospirenone were noted to have advantages in reducing the incidence of adverse reactions and in having additional non-contraceptive benefits that were of importance for the young women to choose a contraceptive. Conclusion. Reliable contraceptives containing minimal hormones, which guarantee minimum side effects and high menstrual cycle control, may become an effective alternative for young women, by enhancing their adherence.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Galina Dikke

Peoples' Friendship University of Russia, Ministry of Education of Russia

Email: galadikke@yandex.ru
Honoured Science and Education, MD, professor of obstetrics, gynecology and reproductive medicine faculty of continuing medical education Moscow 117198, Miklukho-Maklaya str. 8, Russia

Әдебиет тізімі

  1. Дакке Г.Б., Ерофеева Л.В. Особенности репродуктивного поведения молодежи. Акушерство и гинекология. 2013; 12: 96-101. [Dikke G.B., Erofeeva L.V. Featuresofreproductive behavior ofyoung people. Akusherstvo і ginekologiya/Obstetrics and gynecology. 2013; 12: 96-101. (in Russian)]
  2. Уварова E.B. Комбинированная гормональная контрацепция у сексуально активных подростков и молодежи. Русский медицинский журнал. 2008; 16(19): 1232-5. [Uvarova E.V. Combined hormonal contraception in sexually active adolescents and young adults. Russkiy meditsinskiy zhumal. 2008; 16(19): 1232-5. (in Russian)]
  3. Захаров С. Брачность в России: история и современность. Электронная версия бюллетеня «Население и общество» Демоскоп Weekly. 2006; № 261-262. Available at: http://demoscope.ru/ [Zaharov S. Marriages in Russia: history and modernity. The electronic version of the newsletter “Citizens and Society” Demoscope Weekly. 2006; № 261-262. Available at: http://demoscope.ru/ (in Russian)]
  4. Федеральная служба государственной статистики. Женщины и мужчины России. Статистический сборник. 2014. Электронная версия. Available at: http://www.gks.ru [Federal State Statistics Service. Women and men of Russia. Statistical Yearbook. 2014. An electronic version. Available at: http://www.gks.ru (in Russian)]
  5. Бирюкова C.C., Тындик А.О. Регистрация брака и рождение ребенка в биографии россиян: анализ данных текущей статистики. Демографическое обозрение. 2014; 1(3): 33-64.
  6. Щербакова E. Рост числа родившихся продолжает замедляться, число абортов сокращается. Электронная версия бюллетеня «Население и общество» Демоскоп Weekly. 2014; №587-588. Available at: http://www. demoscope.ru
  7. Основные показатели здоровья матери и ребенка, деятельность службы охраны детства и родовспоможения в Российской Федерации. М.; 2013. 200с.
  8. Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin. Drug Investig. 2010; 30(11): 749-63.
  9. Eeming K.L., Sokoloff A., Raine T.R. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception. 2010; 82(2): 178-82.
  10. Winner B., Peipert J.F., Zhao Q., Bucket C., Madden T. Allsworth J.E., Secura G.M. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 2012; 366(21): 1998-2007.
  11. Egarter C., Frey Tirri B., Bitter J., Kaminskyy V, Oddens B.J., Prilepskaya V etal. Women’s perceptions and reasons for choosing the pill, patch, or ring in the CHOICE study: a cross-sectional survey of contraceptive method selection after counseling. BMC Womens Health. 2013; 13: 9. Available at: http:// www. ncbi. nlm. nih.gov/
  12. Ersek J.L., Brunner Huber L.R., Thompson M.E., Warren-Findlow J. Satisfaction and discontinuation of contraception by contraceptive method among university women. Matem. Child Health J. 2011; 15(4): 497-506.
  13. Moreau C., Geland K, Trussed J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007; 76(4): 267-72.
  14. Алесина И.Л. Консультирование женщин как важный инструмент при индивидуальном подборе метода контрацепции. Акушерство и гинекология. 2011; 6: 120-4.
  15. Hatcher R.A., Rinehart W., Blackburn R.r GellerJ.S., Shelton J.D. The essentials of contraceptive technology. Baltimore: The Johns Hopkins Bloomberg School of Public Health, Population Information Program; 2003. 355p.
  16. Halpem V, Lopez L.M., Grimes D.A., Stockton L.L., Gallo M.F Strategies to improve adherence and acceptability of hormonal methods of contraception. (Review). Cochrane Database Syst. Rev. 2013; (10): CD004317. Available at: http://onlinelibrary.wiley.com/
  17. Gallo M.F., Nanda K., Grimes D.A., Lopez L.M., Schulz KF 20 pg versus >20 pg estrogen combined oral contraceptives for contraception. (Review). Cochrane Database Syst. Rev. 2013; (8): CD003989. Available at: http:// onlinelibrary.wiley.com /
  18. Endrikat J., Parke S., Trummer D., Schmidt W., Duijkers I., Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008; 78(3): 218-25.
  19. Ahrendt H.J., Makalova D., Parke S., Mellinger U., Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven- cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5): 436-44.
  20. Oelkers W., Foidart J.M., Dombrovicz N. Welter A., Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endocrinol. Metab. 1995; 80(6): 1816-21.
  21. Losert W., Casals-Stenzel J., Base M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung. 1985; 35(2): 459-71.
  22. Nakajima S.T., Archer D.E, Ellman II. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 pg (Loestrin 24 Fe). Contraception. 2007; 75(1): 16-22.
  23. Карахалис Л.Ю., Жигаленко A.P, Стебло Е.И. Контрацептивные и неконтрацептивные эффекты дроспиренона. Репродуктивное здоровье детей и подростков. 2015; 2: 73-7. [Karahalis L.Yu., Zhigalenko A.R., StebloE.I. Contraceptive and non-contraceptive effects of drospirenone. Reproduktivnoezdorovedetey і podrostkov. 2015; 2:73-7. (in Russian)]
  24. Willis S.A., Kuehl T.J., Spikerman A.M., Sulak P.J. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006; 74(2): 100-3.
  25. Caiyan W., Wen D., Qinping L., Huan S., Ziyan H., Liangdan I et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 pg in a 24+4-day regimen in China. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(5): 355-9.
  26. Fu Y, Mi W., Li L., Zhang H, Wang J., Cheng W et al. Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 pg in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(7): 506-9.
  27. Mansour D., Verhoeven C., Sommer W., Weisberg E., Taneepanichskul S., Melis G.B. et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17[3-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept. Reprod. Health Care. 2011; 16(6): 430-43.
  28. Прилепская B.H., Новикова Е.П. Дроспиренон-содержащие контрацептивные средства - возможности расширяются. Фарматека. 2012; 12: 49-52.
  29. ГеворкянМ.А.,МанухинИ.Б., ТихомировА.Л., Кузнецова F.M Опыт применения дроспиренон-содержащего гормонального контрацептива. Русский медицинский журнал. 2011; 19(1): 24-33.
  30. Тихомиров А.Л. Комбинированная по составу и востребованности гормональная контрацепция. Русский медицинский журнал. 2014; 22(1): 38-40.
  31. Gallo M.F, Lopez L.M., Grimes D.A., Carayon F, Schulz K.F, Helmerhorst F.M. Combination contraceptives: effects on weight. (Review). Cochrane Database Syst. Rev. 2014; (1): CD003987. Available at: http://onlinelibrary.wiley.com/
  32. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000; 62(1): 29-38.
  33. Foidart J.M., Wuttke W., Bouw G.M., Gerlinger C., Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care. 2000; 5(2): 124-34.
  34. Lawrie T.A., Helmerhorst F.M., Maitra N.K, Kulier R., Bloemenkamp K, Giilmezoglu A.M. Types of progestogens in combined oral contraception: effectiveness and side-effects. (Review). Cochrane Database Syst. Rev. 2011; (5): CD004861. Available at: http://onlinelibrary.wiley.com/
  35. Nappi R.E., Albani F, Tonani S., Santamaria V, Pisani C., Terreno E. et al. Psychosexual well-being in women using oral contraceptives containing drospirenone. Funct. Neurol. 2009; 24(2): 71-5.
  36. Apter D., Borsos A., Baumgartner W., Melis G.B., Vexiau-Robert D., Colligs-Hakert A. et a/. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Health Care. 2003; 8(1): 37-51.
  37. Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low- dose oral contraceptive containing drospirenone: results of three multicentre trials. Clin. Drug Invest. 2009; 29(2): 73-8.
  38. Gruber D.M., Huber J.C., Melis G.B., Stagg C., Parke S., Marr J. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 pg and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20 pg and desogestrel 150 mug. Treat. Endocrinol. 2006; 5(2): 115-21.
  39. Marr J., Heinemann K, Kunz M., Rapkin A. Ethinylestradiol 20 pg/ drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. Int. J. Gynaecol. Obstet. 2011; 113(2): 103-7.
  40. Басова O.H., Волков В.Г. Сравнительная характеристика эффективности комбинированных оральных контрацептивов в терапии ПМС: рандомизированное контролируемое исследование. Проблемы репродукции. 2011; 4: 27-31.
  41. Rapkin A.J. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 2008; 53(9): 729-41.
  42. Прилепская B.H., Межевитинова E.A., Сасунова P.A., Иванова Е.В., Летуновская А.Б., Набиева К.Р. Результаты клинического применения препарата, содержащего дроспиренон, у женщин с тяжелой формой предменструального синдрома. Акушерство и гинекология. 2012; 2: 81-5.
  43. Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. (Review). Cochrane Database Syst. Rev. 2012; (2): CD006586. Available at: http://onlineli- brary.wiley.com/
  44. Wong C.L., Farquhar C., Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. (Review). Cochrane Database Syst. Rev. 2009; (4): CD002120. Available at: http://onlinelibrary.wiley.com/
  45. Arowojolu A.O., Gallo M.F., Lopez L.M., Grimes D.A. Combined oral contraceptive pills for treatment of acne. (Review). Cochrane Database Syst. Rev. 2012; (7): CD004425. Available at: http://onlinelibrary.wiley.com/
  46. van Vloten W.A., van Haselen C.W., van Zuuren E.J., Gerlinger C., Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002; 69(4, Suppl.): 2-15.
  47. Maloney J.M., Dietze P. Jr., Watson D., Niknian M., Lee-Rugh S., Sampson-Landers C., Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet. Gynecol. 2008; 112(4): 773-81.
  48. Koltun W, Lucky A. W., Thiboutot D., Niknian M., Sampson-Landers C., KornerP., MarrJ. Efficacy and safety of 3 mg drospirenone/20 mcgethi- nylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008; 77(4): 249-56.
  49. Артымук H.B., Букреева Е.Л. Сравнительная оценка влияния сочетания 3 мг дроспиренона и 20 или 30 мкг этинилэстрадиола на состояние кожи и антропометрические показатели. Фарматека. 2015; 3: 31-3.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2015

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>